×
S&P 500   3,893.82 (+1.27%)
DOW   31,321.20 (+0.91%)
QQQ   294.10 (+1.84%)
AAPL   145.88 (+2.07%)
MSFT   267.82 (+0.60%)
META   171.47 (+1.00%)
GOOGL   2,349.49 (+2.53%)
AMZN   116.35 (+1.77%)
TSLA   728.83 (+4.84%)
NVDA   158.07 (+4.47%)
NIO   22.42 (+7.63%)
BABA   124.10 (+4.18%)
AMD   79.21 (+5.12%)
MU   58.44 (+1.87%)
CGC   2.68 (+1.13%)
T   21.16 (+0.33%)
GE   62.35 (+1.27%)
F   11.59 (+4.79%)
DIS   97.00 (+0.96%)
AMC   14.06 (+11.85%)
PFE   53.12 (+0.70%)
PYPL   74.64 (+1.91%)
NFLX   189.45 (+2.93%)
S&P 500   3,893.82 (+1.27%)
DOW   31,321.20 (+0.91%)
QQQ   294.10 (+1.84%)
AAPL   145.88 (+2.07%)
MSFT   267.82 (+0.60%)
META   171.47 (+1.00%)
GOOGL   2,349.49 (+2.53%)
AMZN   116.35 (+1.77%)
TSLA   728.83 (+4.84%)
NVDA   158.07 (+4.47%)
NIO   22.42 (+7.63%)
BABA   124.10 (+4.18%)
AMD   79.21 (+5.12%)
MU   58.44 (+1.87%)
CGC   2.68 (+1.13%)
T   21.16 (+0.33%)
GE   62.35 (+1.27%)
F   11.59 (+4.79%)
DIS   97.00 (+0.96%)
AMC   14.06 (+11.85%)
PFE   53.12 (+0.70%)
PYPL   74.64 (+1.91%)
NFLX   189.45 (+2.93%)
S&P 500   3,893.82 (+1.27%)
DOW   31,321.20 (+0.91%)
QQQ   294.10 (+1.84%)
AAPL   145.88 (+2.07%)
MSFT   267.82 (+0.60%)
META   171.47 (+1.00%)
GOOGL   2,349.49 (+2.53%)
AMZN   116.35 (+1.77%)
TSLA   728.83 (+4.84%)
NVDA   158.07 (+4.47%)
NIO   22.42 (+7.63%)
BABA   124.10 (+4.18%)
AMD   79.21 (+5.12%)
MU   58.44 (+1.87%)
CGC   2.68 (+1.13%)
T   21.16 (+0.33%)
GE   62.35 (+1.27%)
F   11.59 (+4.79%)
DIS   97.00 (+0.96%)
AMC   14.06 (+11.85%)
PFE   53.12 (+0.70%)
PYPL   74.64 (+1.91%)
NFLX   189.45 (+2.93%)
S&P 500   3,893.82 (+1.27%)
DOW   31,321.20 (+0.91%)
QQQ   294.10 (+1.84%)
AAPL   145.88 (+2.07%)
MSFT   267.82 (+0.60%)
META   171.47 (+1.00%)
GOOGL   2,349.49 (+2.53%)
AMZN   116.35 (+1.77%)
TSLA   728.83 (+4.84%)
NVDA   158.07 (+4.47%)
NIO   22.42 (+7.63%)
BABA   124.10 (+4.18%)
AMD   79.21 (+5.12%)
MU   58.44 (+1.87%)
CGC   2.68 (+1.13%)
T   21.16 (+0.33%)
GE   62.35 (+1.27%)
F   11.59 (+4.79%)
DIS   97.00 (+0.96%)
AMC   14.06 (+11.85%)
PFE   53.12 (+0.70%)
PYPL   74.64 (+1.91%)
NFLX   189.45 (+2.93%)
NASDAQ:ATRC

AtriCure Stock Forecast, Price & News

$43.65
+1.04 (+2.44%)
(As of 07/7/2022 12:28 PM ET)
Add
Compare
Today's Range
$42.24
$43.99
50-Day Range
$35.10
$54.75
52-Week Range
$32.83
$89.18
Volume
1,705 shs
Average Volume
291,895 shs
Market Capitalization
$2.02 billion
P/E Ratio
38.97
Dividend Yield
N/A
Price Target
$83.20

AtriCure MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
91.1% Upside
$83.20 Price Target
Short Interest
Bearish
5.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of AtriCure in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$154,104 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.07) to ($0.85) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.01 out of 5 stars

Medical Sector

460th out of 1,433 stocks

Surgical & Medical Instruments Industry

56th out of 137 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

AtriCure logo

About AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

ATRC Stock News Headlines

AtriCure (NASDAQ:ATRC) Upgraded to Hold at StockNews.com
AtriCure (NASDAQ:ATRC) Hits New 12-Month Low at $38.26
AtriCure - For A Healthy Heart
AtriCure - For A Healthy Heart - RTTNews
AtriCure: Q1 Earnings Snapshot - Greenwich Time
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
875
Year Founded
2000

Company Calendar

Last Earnings
5/03/2022
Today
7/07/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$83.20
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+90.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.8
Research Coverage
5 Analysts

Profitability

Net Income
$50.20 million
Pretax Margin
18.00%

Debt

Sales & Book Value

Annual Sales
$274.33 million
Cash Flow
$0.98 per share
Book Value
$10.53 per share

Miscellaneous

Free Float
44,992,000
Market Cap
$2.02 billion
Optionable
Optionable
Beta
1.15

Social Links















AtriCure Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AtriCure stock.
View analyst ratings for AtriCure
or view top-rated stocks.

What is AtriCure's stock price forecast for 2022?

5 Wall Street research analysts have issued 1 year price objectives for AtriCure's shares. Their ATRC stock forecasts range from $55.00 to $110.00. On average, they anticipate AtriCure's share price to reach $83.20 in the next year. This suggests a possible upside of 90.6% from the stock's current price.
View analysts' price targets for AtriCure
or view top-rated stocks among Wall Street analysts.

How has AtriCure's stock price performed in 2022?

AtriCure's stock was trading at $69.53 on January 1st, 2022. Since then, ATRC shares have decreased by 37.2% and is now trading at $43.65.
View the best growth stocks for 2022 here
.

When is AtriCure's next earnings date?

AtriCure is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for AtriCure
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings data on Tuesday, May, 3rd. The medical device company reported ($0.33) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.33). The medical device company earned $74.58 million during the quarter, compared to the consensus estimate of $71.17 million. AtriCure had a net margin of 17.93% and a negative trailing twelve-month return on equity of 11.66%. The business's quarterly revenue was up 25.8% compared to the same quarter last year. During the same period last year, the business posted ($0.32) EPS.
View AtriCure's earnings history
.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of -$1.12--$1.07 for the period, compared to the consensus estimate of -$1.05. The company issued revenue guidance of $318.00 million-$330.00 million, compared to the consensus revenue estimate of $321.65 million.

Who are AtriCure's key executives?

AtriCure's management team includes the following people:

What is Michael Carrel's approval rating as AtriCure's CEO?

25 employees have rated AtriCure CEO Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among AtriCure's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AtriCure own?

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $43.65.

How much money does AtriCure make?

AtriCure (NASDAQ:ATRC) has a market capitalization of $2.02 billion and generates $274.33 million in revenue each year. The medical device company earns $50.20 million in net income (profit) each year or $1.12 on an earnings per share basis.

How many employees does AtriCure have?

AtriCure employs 875 workers across the globe.

Does AtriCure have any subsidiaries?

The following companies are subsidiares of AtriCure: SentreHEART.
Read More

When was AtriCure founded?

AtriCure was founded in 2000.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for AtriCure is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567.

This page (NASDAQ:ATRC) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.